

## This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Drug platforms</b>			
Galectin-1 (LGALS1) as a prognostic marker of early onset pre-eclampsia	Monitoring levels of serum LGALS1 could help predict risk of severe pre-eclampsia. In 24 pregnant women, circulating levels of LGALS1 were lower during the second trimester in women who developed pre-eclampsia than levels in women who did not. In pregnant mice, <i>Lgals1</i> knockout or an LGALS1 inhibitor administered in early pregnancy increased blood pressure, proteinuria and other symptoms seen in human pre-eclampsia compared with no knockout or no treatment, respectively. Ongoing work includes validating serum LGALS1 as a prognostic marker of pre-eclampsia in a large cohort of pregnant women.	Patent and licensing status undisclosed	Freitag, N. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online June 24, 2013; doi:10.1073/pnas.1303707110 <b>Contact:</b> Sandra M. Blois, Charité-University Hospital Berlin, Berlin, Germany e-mail: <a href="mailto:sandra.blois@charite.de">sandra.blois@charite.de</a>
	<i>SciBX</i> 6(29); doi:10.1038/scibx.2013.777 Published online Aug. 1, 2013		